Form 4: Sarepta Therapeutics CFO Ian Estepan Reports Stock Transactions

Chief Financial Officer of Sarepta Therapeutics, Ian Michael Estepan, reports acquisition and disposal of company stock and stock options.

Summary

• Ian Michael Estepan, CFO of Sarepta Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On March 1, 2024, Estepan disposed of 365 shares of common stock at $126.19 to cover tax obligations related to vesting restricted stock units.
• On the same day, he acquired 6,000 shares of common stock as restricted stock units (RSUs) that vest over four years.
• Estepan also sold 1,200 shares at $128.30 to cover taxes from vesting restricted stock unit awards.
• Additionally, Estepan acquired a stock option for 12,500 shares at an exercise price of $128.67, vesting incrementally from March 1, 2025.
• Following these transactions, Estepan directly owns 39,114 shares of common stock and holds options for 12,500 shares.

Sentiment

Score: 6

Explanation: Neutral sentiment. The transactions are routine and related to compensation and tax obligations. The acquisition of RSUs and stock options is a positive sign, but the sales to cover taxes offset this.

Positives

• The acquisition of 6,000 shares in the form of restricted stock units indicates confidence in the company's future performance.
• The granting of a stock option for 12,500 shares also suggests a positive outlook.

Future Outlook

The vesting schedule of the restricted stock units and stock options suggests a long-term incentive structure for the CFO.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and actions regarding their company's stock.

Comparison to Industry Standards

• Executive compensation packages often include a mix of salary, stock options, and restricted stock units to align management's interests with those of shareholders.
• The vesting schedules and exercise prices are typical components of such compensation plans, designed to incentivize long-term performance.
• Comparing Estepan's holdings and transactions to those of CFOs at similar-sized biotech companies (e.g., BioMarin, Vertex) would provide further context.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding the CFO's holdings and recent trading activity.
• The vesting schedules of the RSUs and stock options align the CFO's interests with long-term shareholder value.

Key Dates